Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IGM Biosciences, Inc. (IGMS : NSDQ)

• Company Description    IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences Inc. is based in Mountain View, California. Number of Employees: 192

• Price / Volume Information    Yesterday's Closing Price: $15.11 Daily Weekly Monthly 20 Day Moving Average: 376,479 shares Shares Outstanding: 42.53 (millions) Market Capitalization: $642.58 (millions) Beta: -0.13 52 Week High: $99.44 52 Week Low: $12.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.80% -12.12% 12 Week -7.02% 0.89% Year To Date -48.48% -38.74%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 325 EAST MIDDLEFIELD ROAD - MOUNTAIN VIEW,CA 94043 USA ph: 650-965-7873 fax: - None http://igmbio.com

• General Corporate Information    Officers Fred Schwarzer - Chief Executive Officer; President and Director Michael Loberg - Chair of the Board of Director Misbah Tahir - Chief Financial Officer Felix Baker - Director M. Kathleen Behrens - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 449585108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 42.53 Most Recent Split Date: (:1) Beta: -0.13 Market Capitalization: $642.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.45 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.10 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.40 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -61.05% vs. Previous Quarter: -2.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -70.14 12/31/21 - -54.67 09/30/21 - -41.37 ROA 03/31/22 - -59.87 12/31/21 - -48.52 09/30/21 - -37.81 Current Ratio 03/31/22 - 7.23 12/31/21 - 8.67 09/30/21 - 13.13 Quick Ratio 03/31/22 - 7.23 12/31/21 - 8.67 09/30/21 - 13.12 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 4.81 12/31/21 - 7.54 09/30/21 - 8.80 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©